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Increasing evidence suggests that abnormal brain accumulation of soluble rather than
aggregated amyloid-β1–42 oligomers (Aβo(1–42)) plays a causal role in Alzheimer’s disease
(AD). However, as yet, animal’s models of AD based on oligomeric amyloid-β1–42
injections in the brain have not investigated their long-lasting impacts on molecular
and cognitive functions. In addition, the injections have been most often performed
in ventricles, but not in the hippocampus, in spite of the fact that the hippocampus
is importantly involved in memory processes and is strongly and precociously affected
during the early stages of AD. Thus, in the present study, we investigated the long-lasting
impacts of intra-hippocampal injections of oligomeric forms of Aβo(1–42) on working and
spatial memory and on the related activation of ERK1/2. Indeed, the extracellular signal-
regulated kinase (ERK) which is involved in memory function had been found to be
activated by amyloid peptides. We found that repeated bilateral injections (1injection/day
over 4 successive days) of oligomeric forms of Aβo(1–42) into the dorsal hippocampus
lead to long-lasting impairments in two working memory tasks, these deficits being
observed 7 days after the last injection, while spatial memory remained unaffected.
Moreover, the working memory deficits were correlated with sustained impairments
of ERK1/2 activation in the medial prefrontal cortex (mPFC) and the septum, two
brain areas tightly connected with the hippocampus and involved in working memory.
Thus, our study is first to evidence that sub-chronic injections of oligomeric forms of
Aβo(1–42) into the dorsal hippocampus produces the main sign of cognitive impairments
corresponding to the early stages of AD, via long-lasting alterations of an ERK/MAPK
pathway in an interconnected brain networks.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neuropathological
disorder that develops over decades, leading to neuronal
loss and cognitive deficits. Memory dysfunction is a core,
defining characteristic of AD (Perry and Hodges, 2000) earliest
manifestations being impairments in episodic memory and in
workingmemory processing (Stopford et al., 2012). Interestingly,
these two forms of memory are sustained by two main cerebral
structures, namely the hippocampus (HPC) and the medial
prefrontal cortex (mPFC), which are early affected in the time-
course development of AD (Morris and Baddeley, 1988; Bondi
et al., 2008; Webster et al., 2014). In addition, long-term memory
seems to be impaired in more advanced stages of the disease
(Tarawneh andHoltzman, 2012). However, the histopathological
causes subtending these gradual memory deficits are still subject
to controversy. Indeed, while the impact of hyperphosphorylated
forms of tau proteins on memory deficits (Mandelkow et al.,
2003) was investigated across the Braak stages (Braak and Braak,
1991), the causal role of the development of β-amyloid peptide
(Aβ) deposits was also scrutinized as an etiological factor of
AD (Hardy and Selkoe, 2002; Thal et al., 2002; Walsh et al.,
2002; Shankar et al., 2008). While determining which of these
biomarkers is the most representative of the disease is still under
debate, recent evidence suggests a strong interplay between Aβ
and tau, with tau acting as a downstream target of Aβ (reviewed
in: Nisbet et al., 2015).
In the human brain, there are two main forms of Aβ
species (Aβ(1–40) and Aβ(1–42)) resulting from the proteolysis
of the amyloid precursor protein (APP; Barthet et al., 2012).
Under normal physiological conditions, the Aβ(1–40) isoform
is the most common isoform contrary to the AD pathology
in which the Aβ(1–42) isoform is the most abundant (Kuo
et al., 1996), having the highest propensity for aggregation and
leading to their accumulation in senile plaques (Andreasen and
Zetterberg, 2008; Lista et al., 2014). However, findings from
some brain patients suffering from AD revealed that amyloid
plaques do not necessarily precede the occurrence of cognitive
declines (Terry et al., 1991; Andreasen and Blennow, 2005).
In contrast, important amyloid deposits have been observed in
cognitively normal people (Nordberg, 2008; Villemagne et al.,
2008). These observations indicate that senile plaques may
not always clinically correlate with AD. Given that, it has
been suggested that small soluble oligomeric species of Aβ
(Aβo(1–42)), rather than amyloid plaques, may be neurotoxic and
responsible for synaptic and network dysfunctions leading to the
physiopathologic consequences of AD (Cleary et al., 2005; Haass
and Selkoe, 2007; Benilova et al., 2012). Therefore, the binding
of soluble Aβ assemblies to cellular membranes might trigger
multiple effects affecting diverse pathways leading gradually to
the cognitive manifestations of the clinical disorder (Mucke
and Selkoe, 2012). To further investigate the synaptotoxicity
of small isomers, experimental approaches have looked at the
behavioral consequences induced by intracerebral injections of
Aβ. Unfortunately, contradictory results have emerged which
appear to depend on the site of injection and the nature
of the peptide (for review: Chambon et al., 2011). To our
knowledge, only a few studies have evaluated the impact of
direct infusion of Aβo(1–42) into the dorsal hippocampus on
memory processes. However, recent findings showed that intra-
hippocampal infusion of Aβo(1–42) affected working memory
when memory performance were evaluated only 10 min after
the injection, suggesting that such deficits could be attributable
to the acute neurotoxic effect of the peptide (Pearson-Leary
and McNay, 2012). In contrast, the long-lasting effects of
oligomeric assemblies of intra-HPC Aβ on working memory,
which is strongly affected in early stages of AD, remain poorly
characterized.
Although multiple mechanisms for Aβ peptide-induced
molecular alterations and consequently memory deficits have
been hypothesized there is considerable evidence implicating a
role for Aβ-induced disruption of kinases critical for memory
(Zhu et al., 2002; Echeverria et al., 2004; Ma et al., 2007). Among
these kinases, the extracellular signal-regulated kinase (ERK) has
often been claimed to be particularly sensitive to Aβ species
during the course of the disease (Ma et al., 2007; Kim and Choi,
2010). However, the direction of ERK regulation by Aβ is far
to end up with a clear consensus, all sorts of ERK responses
to Aβ being reported (Stanciu et al., 2000; Dineley et al., 2001;
Savage et al., 2002; Townsend et al., 2007; Frasca et al., 2008).
On the other hand, ERK regulation in AD appears to be stage-
dependent with initial activation at early stages followed by loss
of activation in advanced AD (Webster et al., 2006). Beside
Aβ modulation of ERK activity, ERK signaling pathway has
been shown to reciprocally regulate APP metabolism and Aβ
production (Cho et al., 2007). As mentioned above, we have also
focused on ERK because a wide variety of studies indicate its
critical importance in synaptic plasticity and memory formation
(Adams and Sweatt, 2002; Nagai et al., 2006). Therefore, the
alteration of the dynamic of ERK activation may alter memory
processes and play a cardinal role in the genesis of memory
deficits in AD.
Altogether and in view of the scarcity of the experiments
exploring the potential long-lasting effect of soluble Aβ, the aim
of this report was to investigate the long-term impact of Aβo(1–42)
injections into the hippocampus on mnemonic and molecular
processes that are sensitive to AD pathology.
In the present series of experiments, we analyzed the
consequences of Aβo(1–42) injections into the CA1 of the dorsal
hippocampus (dCA1) on two working memory tasks and on
a long-term spatial memory, known to be partly sustained by
this brain area. We then examined the effects of intra-dCA1
Aβo(1–42) injections on memory-induced ERK1/2 activation in
a functionally related brain network to better understand how
local changes into the dCA1 could affect a brain circuitry during
memory processing.
MATERIALS AND METHODS
Animals
The subjects were 10-month-old naïve male mice of the C56BL/6
inbred stain obtained from Janvier (St Berthevin, France). Mice
were housed individually with free access to food and water on
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a 12 h light-dark cycle (7:00 AM/7:00 PM) in a temperature-
controlled and ventilated room. All animals were handled during
5 consecutive days before testing which were conducted during
the light phase of the cycle. All experiments were approved
by the local Ethics Committee for Animal Experiments and
were performed in accordance with the European Communities
Council Directive of 1st February 2013 (2010/63/UE).
Surgery
Mice were anesthetized with a ketamine (1 mg/Kg body
weight) − xylazine (10 mg/Kg body weight) solution and placed
on stereotaxic frame. Two stainless-steel guide cannulae (26 G,
8 mm length) were implanted bilaterally 1 mm above the dorsal
hippocampus according to the following stereotaxic coordinates
referenced in mm from the bregma (Paxinos and Franklin, 2001;
AP = −2 mm; L = ± 1, 4 mm; V = −0, 9 mm). Guide cannulae
were fixed in place with Ionoglass dental cement (R&S Paris,
France). All operated mice were manipulated every day and were
allowed to recover in their home cage during 7 days before the
beginning of the experiments.
Aβ(1–42) Preparation
Aβ(1–42) peptide (DAEFRHDSGYEVHHQKLVFFAEDVGS
NKGAIIGLMVGGVVIA) or Aβ(1–42) scramble peptide
(KVKGLIDGAHIGDLVYEFMDSNSAIFREGVGAGHVHVAQ
VEF; rPeptide, Bogart, Georgia, USA) solution were prepared
as described previously (Kuperstein et al., 2010; Broersen
et al., 2011; Brouillette et al., 2012). Vials containing 0.5 mg
of Aβo(1–42)–HFIP (1, 1, 1, 3, 3, 3-Hexafluoro-2-propanol)
films were allowed to defrost at room temperature for 10 min.
Aβo(1–42) was then dissolved in HFIP (Sigma-Aldrich) at a
concentration of 1 mg/mL. The HFIP was evaporated using a
gentle steam of nitrogen gas and the peptide film was dissolved in
500 µL of DMSO (Sigma-Aldrich). DMSO was totally removed
of the solution by eluting the Aβo(1–42) peptide from a 5 ml
HiTrap desalting column (GE Healthcare) with 50 mL of buffer
(pH 7.5) containing (Tris50 mM and EDTA 1 mM). Aβo(1–42)
peptide was then kept at −80◦C in 30 µL aliquots until use. The
concentration of Aβo(1–42)in each sample was measured using a
BCA protein assay kit (Pierce, USA).
Electron Microscopy Analysis
The biophysical and biological properties of the Aβo(1–42) have
been previously characterized (Kuperstein et al., 2010; Broersen
et al., 2011; Brouillette et al., 2012). In our study, the preparation
was analyzed using a transmission electron microscopy (TEM).
Aliquots (5 µL) of the Aβo(1–42) preparation were filed on
carbon-coated grids (Euromedex) for 1 min. The liquid was
absorbed with Whatman paper and 5 µL of dye (2% of uranyle
acetate) was applied on the solution. Then, the samples were
dried at room temperature during 3 min. Images were acquired
using a TEM (LaB6 JEOL JEM2100), and were recorded with a
camera (4 × 4 Gatan). The samples of Aβo(1–42) solution were
analyzed everyday from 24 h to 7 days after preparation. Each
day, the preparation was analyzed 10, 30 or 60 min after thawing.
Aβo(1–42) Injections
Mice were bilaterally injected with either 0.2 µg/ µL of Aβo(1–42)
peptide or Aβ(1–42) scramble peptide or an equal volume of buffer
solution (Vehicle) into the CA1 field of the dorsal hippocampus
(dCA1). Each injection consisted of the infusion of a total 0.5 µL
of solution per side at a rate of 0.1 µL/min via stainless-steel
cannulae (LeGuellec, FRANCE) connected to 1 µL Hamilton
syringe pump system. After injections, both cannulae were left
in place for the next 5 min to prevent reflux of the solution. The
injections were performed once daily for 4 consecutive days.
Histology and Determination
of Beta-Amyloid Deposits
The 10 month-old mice received four infusions of Aβo(1–42)
into the dCA1 and were sacrificed 24 h or 7 days after the last
injection. Then the presence of Aβo(1–42) deposits at the time of
memory testing was determined by immunohistochemistry using
an antibody targeting the Aβo(1–42) peptide, as described below.
Cresyl violet staining was performed to evaluate the potential
neuronal death caused by Aβo(1–42) injections.
Behavioral Procedures
All behavioral experiments were performed on independent
cohort of animals. The general design for these experiments is
depicted in Figure 1.
FIGURE 1 | Experimental design of behavioral experiments. Mice received bilateral, intra-dCA1 injections of Aβo(1–42) or Vehicle solution during 4 consecutive
days (one injection per day). Seven days after the last injection, separate cohorts of mice belonging to the Aβo(1–42) and Vehicle-infused groups were tested for
working or spatial memory function using three different behavioral tasks. Working memory was tested using the sequential alternation task in a T-maze (Aβo(1–42):
n = 10, Aβ(1–42) scramble: n = 10 and Vehicle: n = 18) and the delayed matching to place paradigm in the Morris water maze (Aβo(1–42): n = 8 and Vehicle: n = 9);
Spatial memory was evaluated using the delayed alternation task in the T-maze (Aβo(1–42): n = 13 and Vehicle: n = 7). Cohorts of mice tested in the sequential
alternation task were killed 30 min after the beginning of the test session for pERK1/2 immunohistochemistry.
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Working Memory Tasks
In a first procedure, working memory was tested in a
sequential alternation task in a T-maze (Beracochea et al., 1987;
Vandesquille et al., 2013; Dominguez et al., 2014). In a second
procedure, working memory was evaluated in a Morris water
maze using a modified version of the delayed matching-to-place
paradigm (Steele and Morris, 1999).
SEQUENTIAL ALTERNATION IN A T-MAZE
Mice were trained on a sequential alternation task over a series
of consecutive trials run in T-maze. Indeed, to alternate over a
series from trial to trial, animals have both to remember at a given
N trial the choice made at the N-1 trial, and to reset interfering
information (trials N-2, N-3, . . .) which is one of the main aspect
of workingmemory (Kesner, 2005). This task was chosen because
the alternation behavior inmice is an innate tendency which does
not require the use of any positive or negative reinforcement to
emerge.
Apparatus
Sequential alternation was conducted in a T-maze constructed
of gray Plexiglas which is composed by a stem and two goal
arms (35 × 15 × 10) and a starting box which was separated (as
well as the two arms) from the stem by vertical sliding doors.
The opening and closing of the doors and running latencies
were automatically monitored by a computer. The apparatus was
located at the center of a room with various distal cues located on
the wall and a light of 30 lux.
Training Sessions
Mice were first habituated to the T-maze and distal cues during
2 consecutive days over a 10 min free exploration session
(one session per day). The next day, animals performed a
training session consisting in seven successive trials separated by
a 30 s inter-trial interval (ITI); during this training session, mice
were familiarized with the experimental procedure (opening
and closing of the doors and confinement into the goal arms).
For each trial, mice remained in the start-box for a 30 s ITI.
Then, the door was opened and the mouse was allowed to
enter freely one of the two goal arms; the chosen arm was
closed and the choice was recorded. After a 30 s confinement
period into the chosen arm, the mouse was removed and
brought back to the start-box for a second trial identical
to the first one and this procedure was repeated over the
series of trials. To avoid olfactory cues in the maze, the
apparatus was cleaned using 70% (v/v) ethanol between each
trial.
Test Session
The same general procedure as that used in the training
session was implemented 24 h later, except that the ITI was
lengthened to 90 s. The mean alternation rate was calculated
and was expressed in percentage (number of alternation/number
of trials × 100). Running latencies over the series of seven
trials were expressed as a mean ± SEM. To dissociate memory
deficits from an eventual progressive loss of motivation to
alternate over the series, an 8th trial was added to the series
which was separated from the 7th trial by a shorter ITI
(5 s). All animals failing to alternate at the 8th trial were
excluded.
DELAYED MATCHING TO PLACE
PARADIGM IN THE WATER MAZE
Apparatus
The experiment was conducted in a round tank (150 cm diameter
and 55 cm height) filled with water (21◦C ± 1◦C) made opaque
with white non toxic paint. Two platforms (13 cm diameter)
made of transparent Plexiglas were submerged 1 cm below water
surface. One of the platforms had a 10 cm height cue thereby
indicating its location during the habituation session. Several
distal cues were placed on the walls of the water maze room.
Procedure
Working memory was tested using a modified version of
the delayed matching-to-place paradigm featuring an escape
platform that was relocated for each daily trial set. On the first
day of experiment, animals were subjected to a habituation
session consisting in reaching a cued platform in a maximum
of 90 s. This session was composed by four consecutive trials
in which the platform location and the starting points were
changed among trials. This session was aimed at familiarizing
animals with the water, the room and the platform. At the end
of the habituation phase, working memory was evaluated. For
that purpose, the procedure was composed of four trials per
day during 8 consecutive days, in which the hidden platform
location changed every day. A session was composed of four
trials: a first trial (acquisition trial) in which animals had 90 s
to reach the escape platform; a second trial which was separated
from the first one either by a 60 s or a 30 min ITI (this
ITI was alternated each day during the 8-days-procedure); the
remaining 3rd and 4th trials were separated by a 60 s ITI.
Overall, each animal performed four sessions with 60 s ITI
and four sessions with 30 min ITI between trial 1 and trial 2.
Between each trial, animals were dried and returned to their
home cage under a warming light pending the next trial. The
starting points were randomized and were equidistant from the
platform location. Several measures were used during testing.
The average of escape latency (sec ± SEM) in each trial (1–4)
was determined for each condition (60 s and 30 min ITIs’),
as well as the savings escape latency between trials 1 and 2
corresponding to [(Latency trial 1 – Latency trial 2)/(Latency
Trial 1 + Latency trial 2)] and the swim-speed average (cm/sec).
Performance was recorded by a video camera located above
the maze and interfaced with a computerized tracking system
(ViewPoint, FRANCE).
Long-term Spatial Memory
This procedure was performed in the same T-maze as previously
described above. Mice were submitted to the delayed alternation
task using a forced-trial procedure (Dorey et al., 2012).
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DELAYED ALTERNATION TASK
Initially, mice were submitted to two habituation sessions (one
session per day, 10min) in which animals were allowed to explore
the maze and to familiarize with the environment. They were
then given a training session as described above for the sequential
alternation task. The next day, during the acquisition phase,
animals were forced to enter twice the same goal arm of the maze,
the access to the other arm being blocked by the sliding door.
The two forced trials were separated by a 30 s ITI. Mice were
subjected 24 h later to the test phase in which they were allowed
to enter freely in one of the two goal arms. The correct choice
(alternation behavior) is to enter in the arm opposite to that
entered the day before, during the acquisition session. Animals
remained for 30 s in the chosen arm and were again returned
during 30 s to the starting box for a second free choice trial. This
additional trial was aimed at determining whether the intrinsic
psychomotor ability and motivation of mice to alternate were
not impaired by the treatments, so that any deficits observed
at the previous test trial cannot be ascribed to psychomotor or
motivational impairments. One week later, mice were subjected
to the same experimental conditions except that the blocked arm
of the acquisition phase was the opposite to that of the first
session. Thus, each mouse served as its own control to avoid a
place preference bias.
Immunohistochemistry and Quantification
Animals were anesthetized with an i.p injection of pentobarbital
(100 mg/kg) and perfused transcardially with ice-cold 4%
paraformaldehyde in 0.1M phosphate buffer (PB). Brain were
removed and post-fixed overnight in the same fixation solution.
Then brains were coronally-sectioned (40 µm) on a vibratome
(Leica) and kept at−20◦C in a 30% ethylene glycol, 30% glycerol,
0.1M PB solution until immunohistochemistry experiments
as previously described (Dagnas et al., 2013). Free-floating
sections were incubated for 48 h with either rabbit monoclonal
antibody anti-Aβ(1–42) (1:1000; Invitrogen) or rabbit polyclonal
antibody GFAP (H-50; 1:500; Santa Cruz) or rabbit polyclonal
anti-phospho(Thr202/Tyr204)-ERK1/2 (1:2000; Cell Signaling).
Sections were then incubated with a biotinylated goat anti-rabbit
IgG secondary antibody (1:2000; Jackson immunoresearch)
for 2 h and then incubated with an avidin-biotinylated
horseradish peroxidase complex (ABC complex; Vectastain
Elite kit, Vector Laboratories). The peroxydase reaction was
visualized in a Tris 0.1 M solution containing diaminobenzidine
tetrahydrochloride (DAB) and hydrogen peroxide except for the
GFAP antibody for which we used a DAB Nickel peroxydase
substrate kit (Vector Laboratory). Sections were mounted on
gelatin-coat slides, dehydrated and coverslipped. All images
were acquired using an imaging analysis system (Biocom,
Visiolab 2000, V4.50). The numbers of positive nuclei/mm2
were quantified for pERK in the CA3 field (dCA3) and dentate
gyrus (DG) of the dorsal hippocampus, in the prelimbic (PL)
and infralimbic (IL) areas of the prefrontal cortex, in the
dorsomedial (MS) part of the septum and in the lateral nuclei
of the amygdala (LA) according to Paxinos and Franklin
(2001).
Data Analysis
Statistical analyses were performed using the Statview 5.01
software (SAS Institute). The data were analyzed using one
or two-way factorial analyses of variance (ANOVA), followed
when adequate, by post hoc tests (Fisher’s PLSD). Concerning
the spontaneous alternation procedure, the comparison of
performance with chance were calculated with one-sample t-
test (with hypothesized mean = chances level = 50% for correct
responses). The data were presented as the mean ± SEM and
were considered to be statistically significant when p< 0.05.
EXPERIMENTAL DESIGNS FOR
BEHAVIORAL EXPERIMENTS
Experiment 1
Aβo(1–42) injections into the dCA1 induced working memory
deficits in a sequential alternation task.
Cohorts of 10-month-old mice received intra-dCA1
injections of vehicle (n = 18), Aβo(1–42) (n = 10) or Aβ(1–42)
scramble (n = 10) during 4 consecutive days. Seven days after the
last injection, working memory performance were evaluated in a
sequential alternation task. Mice from the vehicle and Aβo(1–42)
groups were sacrificed 30 min after the beginning of the test
session and pERK1/2 immunohistochemistry were performed.
Two additional home cage control groups injected with vehicle
(n = 5) or Aβo(1–42) (n = 5) were sacrificed directly from their
home cage for immunohistochemistry analyses.
Experiment 2
Aβo(1–42) injections into the dCA1 induced working memory
deficits in a delayed-matching to place paradigm.
Cohorts of 10-month-old mice received intra-dCA1
injections of vehicle (n = 9), Aβo(1–42) (n = 8) during
4 consecutive days. Seven days after the last injection, working
memory was evaluated in a delayed-matching to place paradigm
in a water maze.
Experiment 3
Long-term spatial memory was spared by Aβo(1–42) injections
into the dCA1.
Cohorts of 10-month-old mice received intra-dCA1
injections of vehicle (n = 7), Aβo(1–42) (n = 13) during
4 consecutive days. Seven days after the last injection, long-
term spatial memory performance was evaluated in a delayed
alternation procedure in a T-maze.
RESULTS
Histological Characteristics of the in vivo
Model After 4 Consecutive Intra-dCA1
Injections of Aβo(1–42) Peptide
Temporal Profile of Soluble Aβo(1–42) Injected Solution
In order to evaluate the aggregation state of Aβo(1–42) in our
sample preparation, we assessed an analysis of the Aβo(1–42)
solution using TEM (Figure 2A). Examination of the amyloid
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FIGURE 2 | Histological characteristics of the in vivo model based on four consecutive injections of Aβo(1–42). (A) Transmission electron microscopy (TEM)
analysis of Aβ(1–42) purified solution injected in vivo into the dCA1. The analysis was performed every day during 7 consecutive days at 10, 30 and 1 h after thawing.
The results showed that from day 1 to day 4, the solution was mainly composed of oligomeric Aβo(1–42) assemblies when thawing did not exceed 30 min.
(B) Semi-quantitative analysis of Aβo(1–42) deposits (expressed as mean optical density (OD) in the dHPC) region of mice sacrificed 24 h or 7 days after the last
injection (n = 5 for each group). (C) Low magnification photomicrographs of Aβo(1–42) deposits within the entire dHPC (top) and higher magnification
photomicrographs of the dentate gyrus (DG; bottom) from Aβo(1–42)-injected mice sacrificed 24 h or 7 days after the last injection. (D) Representative dHPC sections
7 days after the last intradCA1 injections of Aβo(1–42) or vehicle solution stained by thionine. Aβo(1–42) intra-dCA1 injections induce neuronal death specifically in the
DG. Effect of intra-hippocampal injections of Aβo(1–42) on GFAP expression in the dorsal hippocampus. (E) Comparison between Aβo(1–42)-injected mice (n = 8) and
Vehicle-injected mice (n = 8). Aβo(1–42) injections into the dCA1 induce an increase of GFAP expression specifically in the dHPC. (F) Low magnification
photomicrographs of GFAP immunopositive cells in the dHPC of Vehicle-injected and Aβo(1–42)-injected mice showing an increase of GFAP immunoreactivity in mice
receiving intra-dCA1 injections of Aβo(1–42). #: Between-group comparisons: ###p < 0.001.
peptide solution from day 1 to day 4 indicated that the
preparation of soluble Aβo(1–42) used was almost exclusively
composed of low-molecular-weight Aβo(1–42) species when
samples were analyzed 10 and 30 min after thawing. In contrast,
when samples were analyzed 1 h after thawing, the Aβo(1–42)
solution presented a high degree of aggregation.Moreover, 7 days
after preparation, Aβo(1–42)solution exhibited almost exclusively
fibrillar and aggregated species. These results led us to use
Aβo(1–42)preparation only 4 days after preparation and more
precisely, 20 min after thawing to ensure that the solution
contained a large majority of low-molecular-weight species of
Aβo(1–42).
Determination of Aβ Deposits After 4 Consecutive
Injections of Aβo(1–42) into the dCA1
Assessment of Aβo(1–42) peptide deposition in the brain of
10 month-old mice was analyzed, using an antibody which
recognizes Aβo(1–42), either 24 h or 7 days after the last injection
using a measure of optic density (OD). As depicted by Figure 2B,
the staining of Aβo(1–42) deposits was restricted to the dHPC
and more specifically in the DG. Otherwise, one-way ANOVA
revealed that Aβo(1–42) deposition was significantly reduced in
mice sacrificed 7 days after the last injection as compared to 24 h-
injectedmice (F(1,8) = 27.047; p< 0.001; Figure 2C). Consistently
with the Aβo(1–42) deposition in the DG, cresyl violet staining
revealed a glial proliferation restricted to the DG 7 days after
the last injection of Aβo(1–42) (Figure 2D). However, these glial
cells were located beneath the cell layer which was moderately
damaged. These results suggest that intra-dCA1 injections of
oligomeric assemblies of Aβo(1–42) was able to induce specific and
very localized neuronal damage.
Determination of GFAP Expression Induced by Intra
dCA1 Injections of Aβo(1–42)
To evaluate the inflammatory effects of local infusions of
Aβo(1–42), we analyzed 7 days after the last injection, the
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immunoreactivity of GFAP in different brain structures.
Figures 2E,F shows that animals receiving Aβo(1–42) exhibited
enhanced GFAP immunostaining which was approximately
three fold higher than that found in vehicle control group
(Aβo(1–42) group: 296.25 ± 33.292 vs. Vehicle group: 83.625 ±
9.453). The one-way ANOVA confirmed a significant between-
groups difference (F(1,14) = 37.746; p < 0.001). Importantly, we
found no GFAP activation in other brains structures studied
(PL, SL, SM, LA; data not shown). These results indicated that
Aβo(1–42) injections into the dCA1 led to a specific activation of
astrocytes in the dorsal hippocampus.
BEHAVIOR
Intra-Hippocampal Injections of Aβo(1–42)
Disrupt Working Memory
Experiment 1: Intra-dCA1 Aβo(1–42) Injections Impair
Working Memory Performance in the Sequential
Alternation Task
Figure 3A (left) shows that all mice performed similarly
during the training session when ITI was 30 s. Specifically, all
performance expressed in percentage of alternation rates were
significantly above chance level (50%) regardless of groups
(Vehicle: 73.814 ± 2.278%; t(13) = 10.452; p < 0.001; Aβo(1–42):
70.020 ± 2.213%; t(9) = 9.045; p < 0.001; Aβ(1–42)scramble:
75.000 ± 2.767%; t(9) = 9.036; p < 0.001). One-way
ANOVA confirmed no significant between-groups difference
(F(2,31) = 1.031; p = 0.36).
In contrast, during test session (Figure 3A right), when
the ITI was increased to 90 s both Vehicle and Aβ(1–42)scramble
groups exhibited performance significantly above chance
(Vehicle: 76.179 ± 2.875%; t(13) = 9.105; p < 0.001;
Aβ(1–42)scramble: 73.350 ± 3.678%; t(9) = 6.348; p < 0.001)
whereas the Aβo(1–42) group responded at chance (56.640 ±
4.439%; t(9) = 1.496; p = 0.16). ANOVA yielded a significant
effect of groups (F(2,31) = 8.364; p = 0.001) and further post hoc
comparisons confirmed that performance in the Aβo(1–42)
group (56.64 ± 4.439%) were significantly lower than those
of Vehicle (76.179 ± 2.875%) and Aβ(1–42) scramble (73.35 ±
3.678%) groups (respectively: p < 0.001 and p = 0.004),
which otherwise did not differ from each other (p = 0.57).
An additional analysis per block of two consecutive trials
during the test session (Figure 3B) showed a significant
between-groups difference (F(2,31) = 11.924; p < 0.001) but
no significant block difference (F(2,62) = 2.010; p = 0.14)
nor groups × blocks interaction (F(4,62) = 1.09; p = 0.36).
However, the Aβo(1–42) group exhibited qualitatively lower
alternation performance on the last two blocks of trials as
compared to the Vehicle and Aβ(1–42) scramble groups [Block
2: Aβo(1–42): 45.000 ± 8.975%; Vehicle: 67.857 ± 8.463% and
Aβ(1–42)scramble: 70.000 ± 8.165%] and [Block 3: Aβo(1–42):
40.000 ± 12.472%; Vehicle: 82.143 ± 6.645%; Aβ(1–42)scramble:
65.000 ± 7.638], whereas no difference was observed on
the first block [Block 1: (Aβo(1–42): 75.000 ± 8.333% vs.
Vehicle: 78.571 ± 6.863% and Aβ(1–42)scramble: 75.000 ±
13.437%].
Interestingly, all groups exhibited alternation rate
significantly above chance at the 8th trial of the series, when ITI
was shortened to 5 s (p < 0.01 in all analyses) and which did
not differed between them (p > 0.5 in all analyses). In addition,
running latencies were similar in all groups [Vehicle: 20.3 ±
0.8 s; Aβo(1–42): 20.5 ± 1.6 s and Aβ(1–42)scramble: 23 ± 3.7 s;
F(2,35) = 1.564; p = 0.22].
Taken together, the whole set of results indicate that
the intra-dCA1 injections of Aβo(1–42) peptide but not of
the Vehicle and Aβ(1–42) scramble peptide led to delay-
dependent working memory impairment tested in the sequential
alternation task.
Experiment 2: Aβo(1–42) Injections into the dCA1
Induced Working Memory Deficits in a
Delayed-Matching to Place Paradigm
In order to confirm the results obtained with the sequential
alternation task, we performed a second test based on the delayed
FIGURE 3 | Intra-CA1 Aβo(1–42) treatment decreases working memory performance in a sequential alternation task in T-maze. Percentage alternation
performance were measured during pre-test (ITI = 30 s) and test (ITI = 90 s) sessions on Vehicle (n = 18), Aβo(1–42) (n = 10) and Aβ(1–42) scramble (n = 10) groups.
(A) Alternation performance were impaired in the Aβo(1–42) group during the test session compared with Vehicle and Aβ scramble groups. (B) Two trials blocks
analysis indicated that alternation performance of Aβo(1–42) group was impaired during successive trials. vs. 50% chance level ∗∗∗p < 0.001; Between-group
comparisons; ###p < 0.001.
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matching to place paradigm, allowing evaluation of working
memory in mice.
Figure 4 shows the impact of local intra-dCA1 infusions
of Aβo(1–42) in mice performing spatial working memory in
the water maze 7 days after the last injection, compared with
mice infused with Vehicle. As described in Figure 4A, all mice
acquired similarly the spatial information under the ITI 60 s
condition regardless of treatment. An ANOVA on mean latency
to reach the platform confirmed nomain effect of group (Vehicle
vs. Aβo(1–42): F(1,15) = 0.629; p = 0.44), a significant trial effect
(F(3,45) = 33.626; p < 0.001) and no significant group × trial
interaction (F(3,45) = 48.215; p = 0.76), confirming that all mice
acquired the task at the same rate. However, when the ITI
between trial 1 and trial 2 was increased from 60 s to 30 min
(Figure 4B), the one factor ANOVA with repeated measures
yielded a significant effect of trials (F(3,45) = 21.176; p < 0.001)
and a significant group × trial interaction (F(3,45) = 3.253;
p = 0.03) but no significant effect of groups (F(1,15) = 3.396;
p = 0.085). The significant group × trial interaction relied on
the fact that Aβo(1–42) treated animals exhibited a significantly
higher escape latency relative to vehicles at trial 2 (ITI = 30 min,
p < 0.001) but not at trials 3 and 4, as the ITI was shortened
to 60 s (p = 0.16 and p = 0.79 respectively). Importantly, the
average swim speed was similar between Vehicle (16.494± 0.671
cm.s−1) and Aβo(1–42) (15.069± 0.597 cm.s−1) groups (p = 0.13)
indicating no effect of treatment on swim speed.
The results were further analyzed with the ‘‘saving’’ parameter
(Figure 4C). The ANOVA analysis with repeated measures
showed a significant main effect of group (F(1,15) = 5.007;
p = 0.04), a significant delay effect (F(1,15) = 24.013;
p < 0.001), as well as a significant groups × delay interaction
(F(1,15) = 11.832; p = 0.003). More specifically, the analysis
of ‘‘saving’’ showed that Aβo(1–42)-treated group does
not exhibit saving as compared to control group at the
30 min ITI (−0.4 ± 0.038 vs. 0.214 ± 0.038 respectively;
p < 0.001). Thus, these results indicated that intra-dCA1
injections ofAβo(1–42) led to delayed-dependent working
memory impairment which was absent when ITI was
shortened.
Experiment 3: Long-term Spatial Memory was
Spared by Aβo(1–42) Injections into the dCA1
We then examined the impact of intra-dCA1 injections of
Aβo(1–42) peptide on a long-term spatial memory using the
FIGURE 4 | Intra-dCA1 Aβo(1–42) treatment decreases working memory performance in a delayed matching to place paradigm in the water maze.
Escape latencies (sec) as well as percentage saving were measured in Aβo(1–42) (n = 8) and vehicle (n = 9) groups. (A) Aβo(1–42) and Vehicle groups showed similar
escape latency values during the four trials when the ITI was fixed at 60 s. (B) Aβo(1–42) group exhibited a reduced escape latency value between trial 1 and trial 2
when ITI was set at 30 min, which was restored to that of vehicle group when ITI was reduced to 60 s. (C) Aβo(1–42) group exhibited a decrease in percentage of
saving when ITI was 30 min compared to vehicle group whereas no saving difference was observed when ITI was 60 s. Saving was expressed as (Latency trial
1–Latency Trial 2)/(Latency trial 1 + Latency Trial 2). Between-group comparisons: ###p < 0.001.
Frontiers in Aging Neuroscience | www.frontiersin.org 8 January 2016 | Volume 7 | Article 245
Faucher et al. Impact of Aβo(1–42) on Memory
FIGURE 5 | Effects of intra-dCA1 Aβo(1–42) injections on spatial delayed
memory in the water maze. Percentage of alternation was measured in
Aβo(1–42) (n = 13) and Vehicle (n = 7) groups at 24 h and 5 s ITI. There was
significant between-group difference when animals were tested 24 h after the
acquisition whereas intra-dCA1 Aβo(1–42) injections did not affect spatial
delayed memory at 5 s ITI.
delayed alternation task in the T-maze. Performance during the
training session (ITI = 30 s) were significantly above chance
(50%; data not shown) in Vehicle and Aβo(1–42) groups (p< 0.01
in both comparisons) and the one-way ANOVA confirmed no
significant group effect (p> 0.10; Figure 5).
Since the alternation performance were similar during the
two test sessions, (p > 0.1), they were pooled for further
statistical analyses. During testing session, as shown in Figure 5
alternation performance in the Vehicle and Aβo(1–42) groups
were significantly above chance level (Vehicle: 77.12 ± 2.335%;
t(9) = 11.614; p< 0.001; Aβo(1–42): 69.374± 3.299%; t(13) = 5.873;
p< 0.001). Again, the ANOVA analysis performed on these data
showed no significant between-group difference (F(1,22) = 3.115;
p = 0.09). Interestingly, both groups alternated significantly
above chance level (50%) at the short-term trial [5 s of the
test session (Figure 5; Vehicle: 80 ± 13.333%; t(9) = 2.250;
p < 0.05; Aβo(1–42): 85.714 ± 9.705%; t(13) = 3.680; p < 0.01)]
and no significant between-groups performance was evidenced
(F(1,22) = 0.126; p = 0.72) indicating that the Aβo(1–42) injection
did not affect the motivation to alternate. These results indicated
that local intra-dCA1 injections of Aβo(1–42)did not impact long-
term spatial memory.
Intra-Hippocampal Injections of Aβo(1–42)
Disrupt Patterns of Test-Induced ERK1/2
Phosphorylation in the
Hippocampo-Prefrontal and
Septo-Hippocampal Pathways
Effects of Aβo(1–42) Injections on Patterns of
Activated/Phosphorylated ERK1/2 (pERK) in the
Dorsal Hippocampus after the Sequential Alternation
Test
We compared the patterns of activated/phosphorylated ERK1/2
(pERK) in the dorsal hippocampus of Vehicle and Aβo(1–42)mice
sacrificed 30 min after the beginning of the sequential alternation
testing session, relative to respective control Home-Cage mice.
The analyses were performed on the DG and CA3 but not on the
CA1which showed no activation of ERK in each group. Two-way
ANOVA evidenced a significant effect of the test (F(1,25) = 17.558;
p < 0.001), of Aβo(1–42) (F(1,25) = 19.735; p < 0.001) and
a significant interaction test × Aβo(1–42) (F(1,25) = 24.089;
p< 0.0001) in DG. As shown in Figure 6A, the interaction test×
Aβo(1–42) was characterized by a significant increase of pERK1/2
in Trained-Vehicle group compared to Home Cage-Vehicle
group (p < 0.001) whereas pERK1/2 levels were similar between
Trained-Aβo(1–42) and matched Home Cage (p = 0.23). Post
hoc analyses confirmed that Trained-Vehicle group exhibited
significantly higher levels of pERK1/2 compared to Trained-
Aβo(1–42) (p< 0.0001).
In the CA3, the two-way ANOVA indicated a significant
test effect (F(1,24) = 87.348; p < 0.0001) but no Aβo(1–42) effect
(F(1,24) = 0.092; p = 0.76) nor significant test × Aβo(1–42)
interaction (F(1,24) = 0.981; p = 0.33). As depicted by the
Figures 6B,C the test effect is characterized by a significant
increase of pERK1/2 levels in Trained-Vehicle and Trained-
Aβo(1–42) compared to matched Home cage groups (both
p < 0.0001). Moreover, no Aβo(1–42) effect was observed in
both Home cage and Trained groups (respectively p = 0.32 and
p = 0.37).
Taken together, our data indicated that Aβo(1–42) infusions
into the dCA1 specifically affects levels of pERK1/2 in the DG
but neither in the CA3 nor in the dCA1.
Distinct Patterns of pERK1/2 in Other Structures
Related to the Hippocampus After the Sequential
Alternation Test
The numbers of pERK1/2 positive cells were also quantified
in the medial prefrontal cortex and more particularly in the
PL and the IL cortices, in the septum (MS) and in the
amygdale (LA) to evaluate whether intra-dCA1 infusions of
Aβo(1–42) specifically in the dHPC resulted in alterations in
working memory related decrease in pERK in other structures
(Figure 7). Two-way ANOVAs on pERK data from each
structure revealed significant test effects [all F > 50; all p< 0.001]
but no Aβo(1–42) effects [PL: F(1,25) = 4.117; p = 0.053; IL:
F(1,25) = 0.003; p = 0.95; MS: F(1,25) = 4.01; p = 0.056;
LA: F(1,24) = 0.776; p = 0.38]. In the PL and MS, two-way
ANOVAs evidenced a significant test × Aβo(1–42) interaction
[PL: F(1,25) = 7.480; p = 0.01; MS: F(1,25) = 8.680; p = 0.01]
which relied on the fact that pERK1/2 increased in Trained-
Vehicle compared to respective Home cage (PL: p = 0.003;
MS: p < 0.0001) and that pERK1/2 levels were significantly
lower in Trained-Aβo(1–42) compared to Trained-Vehicle (both
p < 0.001). In contrast, no significant test × Aβo(1–42)
interactions were observed in IL and LA [IL: F(1,25) = 0.045;
p = 0.83; LA: F(1,24) = 0.783; p = 0.38]. Further post-hoc
analyses confirmed no group difference between Trained-
Aβo(1–42) and Trained-Vehicle groups in these areas (both
p> 0.5).
The whole set of results indicated that intra-dCA1 injections
of Aβo(1–42) led to pERK1/2 impairment specifically in the PL
Frontiers in Aging Neuroscience | www.frontiersin.org 9 January 2016 | Volume 7 | Article 245
Faucher et al. Impact of Aβo(1–42) on Memory
FIGURE 6 | Effects of intra-dCA1 Aβo(1–42) injections on levels of phosphorylated ERK1/2 (pERK) in the dorsal hippocampus. Tested animals were killed
30 min after the beginning of the sequential alternation test session. Levels of pERK were measured in the dorsal DG and the dorsal CA3 from Vehicle-injected mice
(home-cage: n = 5; Tested: n = 10) and Aβo(1–42)-injected mice (home-cage: n = 5; Tested: n = 9). (A) Tested-related increase of pERK in the DG was abolished by
Aβo(1–42) injections. (B) In the dorsal CA3, Aβo(1–42) had no effect on pERK levels in comparison with Vehicle, regardless of home-cage or tested conditions. (C)
Representative photomicrographs of pERK immunoreactivity within the dCA1, DG and dCA3 of Trained-Vehicle (top) and Trained-Aβo(1–42) (bottom) groups. ∗∗∗: Test
effect; ###: Between-group comparisons.
and the MS, while sparing the IL and the LA. These data suggest
that local intra-dCA1 injections of Aβo(1–42) drive changes in the
PL and MS, two areas implicated in working memory.
DISCUSSION
We found that Aβo(1–42) infusions into the dorsal hippocampus
(dCA1) induced strong deficits in working memory but not
in spatial memory when mice were tested 7 days after the
last injection. However, the working memory deficits cannot
be directly linked to specific dCA1 dysfunction. Indeed, we
observed differences between the location of the primary
injection site in the dCA1 and both Aβo(1–42) deposits
and neurodegeneration, which are located in the DG area.
Even though we have no experimental explanations for this
phenomenon, the accumulation of Aβo(1–42) deposits in the
DG could result from a mechanistic effect of the procedure
used based on repeated injections, which may weaken the
tissues and allowed the dispersion of the solution in the
DG area. In addition, Aβo(1–42) infused into the dCA1 was
shown to impede the sequential alternation-induced activation
of ERK1/2 in several brain structures, including the dorsal
hippocampus (specifically the DG area but not the dCA1 nor
the CA3), the pre-limbic cortex and the medial septum. Since
the cognitive and molecular alterations were observed at a time
at which amyloid plaques were no longer visible in the dorsal
hippocampus, it seems reasonable to think that local infusion
of Aβo(1–42) has induced long-lasting molecular and cellular
alterations including neuro-inflammatory processes that alter
memory function.
As memory deficit constitutes the core symptom of AD,
previous studies have used different animal models of AD to
investigate the memory impairments that can occur during
the development of the disease. The effect of Aβ peptides on
different forms of memory using intracerebral injections have
been contradictory and appear to depend on the site of injection,
the nature of the peptide and the type of memory which was
taxed (for review: Chambon et al., 2011; Webster et al., 2014). In
studies with transgenic models of AD, results varied depending
on age, strain and memory task. Moreover, there is no clear
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FIGURE 7 | Effects of intra-dCA1 Aβo(1–42) injections on levels of pERK in other structures related to the hippocampus. The same animals as depicted in
Figure 6 were used for these analyses. (A) In the mPFC, levels of pERK were measured in the prelimbic (PL) and infralimbic (IL) cortices. Intra-dCA1 Aβo(1–42)
injections abolished tested-related increase in pERK only in the PL. (B) In the septum, pERK1/2 levels were inhibited by dCA1 infusions of Aβo(1–42). In the lateral
amygdala (LA), Aβo(1–42) had no effect on pERK, regardless of home-cage or tested conditions. ∗∗∗: Test effect; ###: Between-group comparisons.
relationship between the appearance of amyloid plaques and
working or episodic memory impairment (for review: Hall and
Roberson, 2012). For example, working memory impairments in
T/Y maze alternation or radial arm maze were shown before the
appearance of Aβ(1–42) plaques in Tg2576 mice (King et al., 1999;
Arendash et al., 2004; Ohno et al., 2004), and J20 mice (Lustbader
et al., 2004) while no deficit was found for PDAPP (Nilsson et al.,
2004), 5 × FAD (Oakley et al., 2006; Shukla et al., 2013) or 3 ×
Tg mice (Carroll et al., 2007).
Numerous studies have addressed the effects of central
Aβ(1–42) infusion on learning and memory (Chambon et al.,
2011) but no consistent results have emerged (Ghasemi et al.,
2014). While some studies reported spatial memory impairment
in water maze test after Aβ infusion (Majlessi et al., 2012), some
others failed to show any memory deficits. Given that, some
authors tried to potentiate Aβ toxicity with additional brain
injuries such as ischemia (Watanabe et al., 2008), co-injection
with ibotenic acid (Morimoto et al., 1998; Hruska and Dohanich,
2007) or co-injection with dexamethasone (Yao et al., 2011; Li
et al., 2012). Among the few studies that have investigated the
impact of local injections of Aβ into the dorsal hippocampus,
most of them were infusing aggregated forms of Aβ(1–42).
Looking at short-term or workingmemory, these studies revealed
impairment for spatial and non-spatial information when the
animals were tested at delayed time-points after Aβ(1–42) infusion
(Winkler et al., 1994; Hruska and Dohanich, 2007; Christensen
et al., 2008).
However, the aim of our experiments was to target an
earlier stage of the disease by focusing on the oligomeric
species of Aβ that have been hypothesized to be responsible
for the neurotoxic effect of the peptide (Haass and Selkoe,
2007; Viola and Klein, 2015). This is why we infused small
oligomeric Aβ(1–42) peptide once daily for 4 consecutive days
into the dorsal hippocampus and tested the animals 7 days
after the last injection, a time period at which the peptides are
no longer observable. Interestingly, our data clearly show no
impairment of spatial memory per se (short- or long-term) but of
working memory-related processes. As illustrated in Figure 3B,
the impairment in the T-maze alternation task appears to be
caused by proactive interferences as performance of experimental
animals decreased dramatically only on the second block of
trials. This impairment is somewhat reminiscent of previous
studies from our group having shown higher sensitivity to
proactive interferences in agedmice (Vandesquille et al., 2013) or
mice intoxicated with chronic alcohol consumption (Beracochea
et al., 1987; Dominguez et al., 2014) that might be related
to hippocampal dysfunction. Although poorly investigated this
higher sensitivity in proactive interferencemight constitute a first
sign of cognitive decline in AD as it has been suggested by recent
clinical data on amnesic MCI (Crocco et al., 2014).
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The maintenance of information in memory over a short
period of time is another aspect of working memory and this
process which allows the binding of the different features of the
learning situation, has been claimed to be the first to be impaired
as a result of AD (Parra et al., 2009, 2010). This binding process
which relies on the hippocampus (Parra et al., 2010) could be
investigated in animals with the delayed matching to place task
(DMTP task) in which the spatial information needs to be held
in memory during a certain period of time until its use. The
infusion of Aβo(1–42) into the dorsal hippocampus resulted in a
clear time-dependent impairment when the ITI was increased
from 60 s to 30 min. Therefore, by analogy with human studies it
might be speculated that platform-location binding impairment
in this spatial working memory task can be specifically related to
pathological changes induced by Aβo(1–42) injection. Again, this
might be a sensitive measure in preclinical stages of the disease
(Parra et al., 2009, 2010; Pertzov et al., 2015).
The delayed spatial alternation task is showing that long-
term spatial memory was not affected by the intra-hippocampal
injection of Aβo(1–42). This is somewhat unexpected because
the hippocampus is strongly involved in the different phases
of spatial memory (Morris et al., 1982; Riedel et al., 1999;
McGregor et al., 2004; Martin and Clark, 2007). Parsimonious
explanations would be to consider that either the Aβ toxicity is
not equivalent to a lesional effect or the extent of hippocampal
damages was not large enough to impede spatial learning (Moser
et al., 1993). More likely, the neuropathological mechanisms
induced by the Aβ infusion were too premature to alter
spatial learning in tasks that are not very challenging. In
support of this assumption it has been shown in Tg2576 mice
that place cells degradation was observed at 16 but not at
3 months of age (Cacucci et al., 2008). No intermediary ages
were studied but in the same mouse line, although synaptic
plasticity and spine density were decreased in 4–5 month-old
mice (Jacobsen et al., 2006) impairment in spatial learning
was observed only from 6–7 months of age and accumulation
of Aβ40 and Aβ42 appeared at 6–9 months (Lee and Han,
2013). Therefore, the lack of spatial memory impairment in
the Aβo(1–42)-treated mice might correspond to a too early
stage of the neuropathological alterations caused by Aβo(1–42)
injections.
The aim by using the immunohistochemistry with ERK1/2
was twofold: first, to analyse the Aβ influence on ERK1/2
activation and therefore, on memory formation; second, to
pinpoint at a network level the consequences of hippocampal
dysfunction. It is well documented that the activation of
MAPK/ERK signaling cascade reflects the critical participation
of different brain structures in memory formation (Dineley et al.,
2002, 2007; Westerman et al., 2002; Sweatt, 2004; Trifilieff et al.,
2006, 2007; Hort et al., 2007; Hoefer et al., 2008; Kim and
Choi, 2010). Our results indicate that spontaneous sequential
alternation induced ERK1/2 activation in all the investigated
structures except in the area CA1.The lack of test-induced
pERK in the CA1 could rely on the fact that (in contrast
to the other structures) the delay of sacrifice did not allow
detection of this marker. Nevertheless, in a parallel experiment
(not reported in the present study), we showed an important
test-induced activation of pCREB in the dCA1which was blocked
by Aβo(1–42). However, working memory impairments caused
by local intra-dCA1 injections of Aβo(1–42) were associated
with blockade of p-ERK1/2 immunoreactivity only in some
brain structures that may constitute a functional network. The
experiments were conducted 7 days after the last Aβ injection
when most of the peptide has already been metabolized. This
suggests that the absence of ERK1/2 activation corresponds
to synaptic and plasticity detrimental effects that have been
triggered by the direct impact of Aβ on cellular signaling.
In indirect support of these data, soluble oligomers have
been shown to directly interfere with the NMDA/ERK/CREB
signaling pathway by blunting its activity in cortical neurons
of Tg2576 mice and in primary hippocampal neurons (Ma
et al., 2007). However, apparent conflicting reports have shown
that ERK1/2 activation induced in the amygdala by cued fear
conditioning was even more stimulated in APP transgenic mice
(España et al., 2010). As a consequence, to better elucidate
the mechanisms upstream to the delayed effects we found,
it would be valuable to measure testing-induced ERK1/2
activation immediately after the last Aβ intra-hippocampal
infusion.
The absence of testing-induced activation of ERK1/2 in the
Aβo(1–42)-treated mice was observed only in a subset of the
selected brain structures, namely the hippocampus with the
DG, the medial septum and the pre-limbic cortex. Interestingly,
these brain structures are anatomically and functionally linked
(Thierry et al., 2000; Vertes et al., 2004; Spellman et al., 2015).
It has been recently shown that the hippocampal-prefrontal
interplay during spatial workingmemory encoding wasmediated
by gamma-frequency synchrony between the two structures
(Spellman et al., 2015). In addition, the well documented
septo-hippocampal axis is continuously receiving more evidence
demonstrating the critical role played by the medial septum in
the regulation of hippocampal spatial representation (Mamad
et al., 2015). Further, ERK1/2 activation was not affected in the
infra-limbic cortex and the lateral amygdala of the Aβo(1–42)-
treated mice. These two brain structures are proposed to be
part of another anatomical and functional system involved in
the development of habits and in autonomic activity (Killcross
and Coutureau, 2003; Vertes et al., 2004). The latter system
is not supposed to be deeply involved in working memory.
Altogether, our results support the view of an impairment of
a specific neuronal network including the medial septum, the
hippocampus and the pre-limbic cortex in Aβo(1–42)-injected
mice, and suggest that Aβo(1–42)-associated working memory
impairments may be related to the functional disruption of this
network.
In conclusion, our results indicate that Aβo(1–42) injections
into the dCA1 lead to impairment of different aspects of working
memory associated with ERK1/2 dysfunction in a brain circuitry
involving the hippocampus, medial septum and pre-limbic
cortex. Moreover, these cognitive and molecular alterations were
observed 7 days after the last injection, at a time where amyloid
deposits were no longer observed. These results lead us to suggest
that the in vivo mouse model of AD based on four consecutive
intra-dCA1 injections of Aβo(1–42) could constitute a valuable
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tool to study the Aβo(1–42) impact in the hippocampus which
could characterize the very early stage of AD, even though in the
general frame of AD, it is focused on a specific brain area which
did not reflect the widespread damage occurring during the time-
course of the disease. However, this model gives us new insights
on the way local Aβ-induced neuropathology would spread to a
neuronal network.
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